BRIEF-Azurrx Biopharma CEO Issues Letter To Shareholders

Reuters

09 Jan 2021

Jan 8 (Reuters) - AzurRx BioPharma Inc :

* AZURRX BIOPHARMA CEO ISSUES LETTER TO SHAREHOLDERS

* AZURRX BIOPHARMA INC - FOR MS1819 CO REMAINS WELL ON TRACK FOR MEETING OUR PREVIOUSLY-ANNOUNCED CLINICAL MILESTONES

* AZURRX BIOPHARMA INC -FOR MS1819, EXPECT TOP LINE DATA FROM OUR PHASE 2B OPTION 2 MONOTHERAPY TRIAL IN Q1 2021

* AZURRX BIOPHARMA INC - CO EXPECTS DATA FROM PHASE 2 CF COMBINATION THERAPY TRIAL (MS1819 + PERT) IN Q2 2021

* AZURRX BIOPHARMA INC - CO ANTICIPATES ENTERING INTO CLINIC WITH TWO MICRONIZED NICLOSAMIDE CLINICAL PROGRAMS IN FIRST HALF OF 2021

Source text for Eikon: Further company coverage:

((reuters.briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2102956603"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2102956603\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2102956603?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-01-09 01:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2102956603","market":"us","top_or_hot":-1,"title":"BRIEF-Azurrx Biopharma CEO Issues Letter To Shareholders","media":"Reuters","content":"<html><body><p>Jan 8 (Reuters) - AzurRx BioPharma Inc   :</p><p>   * AZURRX BIOPHARMA CEO ISSUES LETTER TO SHAREHOLDERS</p><p>   * AZURRX BIOPHARMA INC - FOR MS1819 CO REMAINS WELL ON TRACK FOR MEETING OUR PREVIOUSLY-ANNOUNCED CLINICAL MILESTONES</p><p>   * AZURRX BIOPHARMA INC -FOR MS1819, EXPECT TOP LINE DATA FROM OUR PHASE 2B OPTION 2 MONOTHERAPY TRIAL IN Q1 2021</p><p>   * AZURRX BIOPHARMA INC - CO EXPECTS DATA FROM PHASE 2 CF COMBINATION THERAPY TRIAL (MS1819 + PERT) IN Q2 2021</p><p>   * AZURRX BIOPHARMA INC - CO ANTICIPATES ENTERING INTO CLINIC WITH TWO MICRONIZED NICLOSAMIDE CLINICAL PROGRAMS IN FIRST HALF OF 2021</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Azurrx Biopharma CEO Issues Letter To Shareholders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Azurrx Biopharma CEO Issues Letter To Shareholders\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-01-09 01:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 8 (Reuters) - AzurRx BioPharma Inc   :</p><p>   * AZURRX BIOPHARMA CEO ISSUES LETTER TO SHAREHOLDERS</p><p>   * AZURRX BIOPHARMA INC - FOR MS1819 CO REMAINS WELL ON TRACK FOR MEETING OUR PREVIOUSLY-ANNOUNCED CLINICAL MILESTONES</p><p>   * AZURRX BIOPHARMA INC -FOR MS1819, EXPECT TOP LINE DATA FROM OUR PHASE 2B OPTION 2 MONOTHERAPY TRIAL IN Q1 2021</p><p>   * AZURRX BIOPHARMA INC - CO EXPECTS DATA FROM PHASE 2 CF COMBINATION THERAPY TRIAL (MS1819 + PERT) IN Q2 2021</p><p>   * AZURRX BIOPHARMA INC - CO ANTICIPATES ENTERING INTO CLINIC WITH TWO MICRONIZED NICLOSAMIDE CLINICAL PROGRAMS IN FIRST HALF OF 2021</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((reuters.briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2102956603","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2102956603","pubTimestamp":1610127354,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 8 (Reuters) - AzurRx BioPharma Inc   :   * AZURRX BIOPHARMA CEO ISSUES LETTER TO SHAREHOLDERS   ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-Azurrx Biopharma首席执行官致股东信","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZRX":0.9},"content_text":"Jan 8 (Reuters) - AzurRx BioPharma Inc   :   * AZURRX BIOPHARMA CEO ISSUES LETTER TO SHAREHOLDERS   * AZURRX BIOPHARMA INC - FOR MS1819 CO REMAINS WELL ON TRACK FOR MEETING OUR PREVIOUSLY-ANNOUNCED CLINICAL MILESTONES   * AZURRX BIOPHARMA INC -FOR MS1819, EXPECT TOP LINE DATA FROM OUR PHASE 2B OPTION 2 MONOTHERAPY TRIAL IN Q1 2021   * AZURRX BIOPHARMA INC - CO EXPECTS DATA FROM PHASE 2 CF COMBINATION THERAPY TRIAL (MS1819 + PERT) IN Q2 2021   * AZURRX BIOPHARMA INC - CO ANTICIPATES ENTERING INTO CLINIC WITH TWO MICRONIZED NICLOSAMIDE CLINICAL PROGRAMS IN FIRST HALF OF 2021Source text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}